Reta-30mg

Form: Lyophilized powder (30mg)

🔬 Retatrutide — Overview

Retatrutide (development name LY-3437943) is an investigational peptide-based therapeutic designed as a triple hormone receptor agonist acting on:

• Glucagon-like peptide-1 receptor (GLP-1R)
• Glucose-dependent insulinotropic polypeptide receptor (GIPR)
• Glucagon receptor (GCGR)

This triple agonism is intended to simultaneously modulate metabolic pathways involved in glycemic control, appetite regulation, energy balance, and weight loss, making Retatrutide a leading candidate in obesity and type 2 diabetes research and clinical trials. It remains experimental and not currently FDA-approved.

---

📌 Brief Functional Description

• Triple receptor agonist peptide: designed to activate GLP-1, GIP, and glucagon receptors to coordinate insulin secretion, appetite suppression, and metabolic regulation.
• Clinical research focus: obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and related cardiometabolic endpoints.

---

🧪 Chemical & Structural Information

🔢 CAS Number

• 2381089-83-2 — the registered CAS for Retatrutide.

🧬 Molecular Formula

• C221H342N46O68 — the elemental composition of the peptide backbone with modifications.

⚖️ Molecular Weight

• ≈4,731 g/mol (average) — approximate molecular mass of Retatrutide.

---

🧬 Structure & Sequence Features

Retatrutide is a synthetic peptide with engineered amino-acid substitutions and lipid/side-chain modifications to optimize receptor binding and pharmacokinetics. Its sequence includes modified residues to improve stability and potency across all three targeted receptors.

A simplified representation (one-letter fragments) reflects peptide backbone motifs tailored to GLP-1, GIP, and glucagon receptor engagement, though the full structure is long and complex.

---

🧠 Mechanism & Research Context

• Triple agonism: Retatrutide engages GLP-1, GIP, and glucagon receptors, linking incretin signaling with glucagon pathways to effect weight loss and glycemic improvements more robustly than single or dual agonists.
• The additional glucagon receptor activity is hypothesized to enhance energy expenditure and fat metabolism beyond what dual GLP-1/GIP compounds deliver.

---

⚠️ Safety & Regulatory Notes

• Retatrutide is still investigational and not approved by regulatory bodies like the FDA for general use; it remains in Phase 2/3 clinical trials.

---

🧪 Quick Reference

Property	Detail
Name	Retatrutide (LY-3437943)
CAS #	2381089-83-2
Molecular Formula	C221H342N46O68
Molecular Weight	~4,731 Da
Type	Synthetic modified peptide triple agonist
Mechanism	GLP-1, GIP, and glucagon receptor agonist
Research Use	Obesity, diabetes, metabolic disease clinical trials

Notice: For Research Use Only. Not for human or veterinary use.